Ontunisertib (AGMB-129)
Fibrosis (unspecified)
Phase 1Active
Key Facts
About Agomab Therapeutics
Agomab Therapeutics is a Belgium-based biotech focused on developing transformative treatments for fibrosis by modulating key growth factor pathways like TGFβ. The company successfully completed a $200 million IPO in February 2026, providing capital to advance its clinical pipeline, which includes both systemic and organ-restricted candidates. Its disciplined strategy targets established biology with innovative drug design to improve efficacy and safety profiles in a market with significant unmet need.
View full company profileTherapeutic Areas
Other Fibrosis (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| AGMB-101 | Agomab Therapeutics | Phase 1 |